Connect with us

BUSINESS

BetterLife Pharma Inc. (OTCMKTS:PVOTF) Announce Proposed Merger With Altum Biotechnology and Release Exploratory Study Results

Published

on

BetterLife Pharma Inc. (OTCMKTS:PVOTF) has announced the securing of lock-up agreements from Altum Pharmaceuticals Inc.’s shareholders representing around 67.12% of Altum’s outstanding common stock.

BetterLife seeks merger with Altum

Following the move, BetterLife is planning to approach Altum Board regarding a potential “merger of equals” deal to take place through a Plan of Arrangement. If BetterLife and Altum do not reach an agreement regarding a merger, BetterLife is planning to initiate a take-over bid for the acquisition of all Altum’s common shares. According to the terms of the suggested acquisition, BetterLife will issue around 4.582 shares of its common stock for every Altum common share. This will be in total proceeds of around $36.1 million.

However, the proposed acquisition deal for Altum shares is subject to the necessary approval and meeting of due diligence conditions. So far, BetterLife has been reviewing materials and published research claims regarding the pipeline products of Altum.

Ahmad Doroudian, the CEO of BetterLife, indicated that he was pleased that most Altum shareholders had agreed on a merger with BetterLife. Doroudian added that the completion of the merger transaction will be a major milestone for BetterLife in its path to becoming a premier biotechnology company with a robust pipeline for unmet patient needs globally.

Exploratory study results released

Recently, BetterLife announced its exploratory study results on the treatment of a group of confirmed coronavirus cases in Wuhan by the journal Frontiers of Immunology. The authors examined the disease course in the study in a group of 77 participants with the confirmed novel coronavirus. These were patients admitted to Union Hospital, Tongji Medical College, in Wuhan from January 16 to February 20, 2020. The subjected evaluated in the study were those of only moderate coronavirus cases.

The lead author of the study, Dr. Eleanor Fish, indicated that interferons are usually the first line of defense when it comes to virus infections. However, in the case of coronaviruses, they have co-evolved and can block the interferon response. Eleanor added that interferon treatment can easily override the virus’s inhibitory effects.

BUSINESS

Fire & Flower Holdings Corp (OTCMKTS:FFLWF) Licenses Its Hifyre Technology Platform And Fire & Flower Brand To American Acres For Dispensaries In Nevada, Arizona, And CA

Published

on

Fire & Flower Holdings Corp (OTCMKTS:FFLWF) agreed to license its store operating system, Hifyre technology platform, and Fire & Flower brand for the dispensaries based in California, Nevada, and Arizona to American Acres Managers. It helps the company to improve retail functionality in these high growth and competitive markets.

An option to take over American Acres

As per the terms of the pact, Fire & Flower can take over American Acres at a reduced rate to the prevailing market price. It is subject to adult-use cannabis legalization in the US or with the permission of TSE policies.

CEO of Fire & Flower, Trevor Fencott, said the company is strongly positioned its technology, brand, and operating system to enter the vital global markets. It is on the backdrop of establishing the biggest retail network for legalized cannabis products in Canada.

Hyfire technology elevates margins and streamlines customer experiences. It keeps Fire & Flower in a unique position to stand ahead in the competitive cannabis markets in the US.

Fencott further said an agreement with American Acres prepares it with technology-activated stores in the US to clinch the emerging opportunities in the legalization of adult-use cannabis. The company anticipates the inauguration of its first branded store in Palm Springs, California, in H1 2021.

Adds 200,000 members to its Spark Perks program

Fire & Flower achieved the target of 200,000 members in its Spark Perks program across the retail network. The Spark Perks Program members receive benefits like members-only events, special deals, Rapid Delivery, curbside pickup, and click and collect checkout. Anyone can join the Spark Perks Program for free, and no need to make the purchase.

Fencott said the program allows it to measure feedback directly from 200,000 cannabis customers, who spend a lot on each transaction. The company reported a 30% increase in members QoQ. It can understand the customer preferences and offer tailor-made products to suit their needs.

The customers in the Fastlane mode spend 53% compared to non-members. President of Hifyre, Matthew Hollingshead, said Fire & Flower’s Digital Retail and Analytics platform provides a significant value proposition in both global and domestic markets.

Continue Reading

BUSINESS

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) Commences Clinical Study Of CUREfilm Blue To Treat Erectile Dysfunction

Published

on

Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) commenced the initial PK (Pharmacokinetics) trial that supports the previously approved IND application with the US FDA. The company initiated this application through the pathway of 505(b)(2) drug approval. It is continuing the feedback obtained from the US FDA to support the clinical developmental plans for its ED drug formulation – CUREfilm Blue.

Oral administration of CUREfilm Blue

Cure Pharmaceutical’s ED drug – CUREfilm Blue will be administered orally to erectile dysfunction in men. The drug is developed using ingredients like sildenafil citrate film, which is a key ingredient in Viagra. It uses the proprietary and patented CUREfilm, the fast-dissolving drug platform, to deliver sildenafil citrate. The new product of Cure Pharmaceutical expects to offer an improved and convenient experience for men to improve their performance.

CSO of Cure Pharmaceutical, Vered Gigi, said the company is pleased to advance CUREfilm Blue for humans’ trials. CEO of Cure Pharmaceutical, Robert Davidson, said it is an important milestone in its clinical development program and uses a patented drug delivery platform to enhance men’s experience.

The company seeks expedited regulatory approval from the US FDA to introduce the product in the market and help men who struggle in gaining and maintaining an erection to improve their experience.

The demand for ED drugs worldwide expects to reach $6.6 billion by 2025 by growing at a CAGR of 6%.

Sera Labs launches advertising campaign

Sera Labs, a Cure Pharmaceutical subsidiary, commenced a digital advertising campaign for sleep A.S.A.P, the Nutri-Strips thin-film product. It also introduced the ad campaign for this innovative sleep aid drug on TV and Radio. The innovative solution offered by Sera Labs will solve the sleep problems faced by Americans.

The demand for sleep aids worldwide expects to grow at a CAGR of 6.8% to reach $112.7 billion in 2025 from $81.2 billion in 2020.

The national ad campaign, which will begin in over 15 significant markets, targets 70% of the US’s adult population. It will coincide with the sleep awareness month across the nation. The benefits offered by Nutri-Strips’ RAD₃ in promoting sound sleep will be highlighted in the ad campaign.

Continue Reading

BUSINESS

Curaleaf Holdings Inc (OTCMKTS:CURLF) Inaugurates Third Branded Store In Maine: Introduces Select Elite Cartridges In Utah

Published

on

Curaleaf Holdings Inc (OTCMKTS:CURLF) inaugurated its 101st store nationwide and the third branded store in Maine to provide high-quality patient care, convenient curbside pickup, and education.

Communities get access to high-quality medical products

The first Bangor-based Curaleaf branded store provides access to premium quality medical cannabis products such as the number one cannabis oil brand – Select to the local communities. General Manager at the Maine location of Curaleaf, Scott Reed said the company is excited to provide access to high-quality medical products in Maine.

Serves patients Ellsworth and Auburn

Curaleaf serves patients in Ellsworth and Auburn for more than 10 years. The company opens a new store in Bangor to improve its connections with the local patients.

Curaleaf expands its reach into Utah with high-quality products like Select Elite cartridges. The company acquired Select brand in February 2020. Curaleaf’s cannabis oil brand, the number one brand in America’s – Select, is available in 17 states such as Florida, California, Connecticut, Colorado, Arizona, Michigan, Maine, Massachusetts, Oklahoma, Nevada, New York, Maryland, Pennsylvania, Oregon, and Utah.

Select Elite is available immediately at its pharmacy in Utah. Medical patients across the state can access the Select brand products soon at medical cannabis pharmacies. Curaleaf being a leading licensed provider of cannabis products serves more than 18,400 active patients in Utah. The patients can enjoy a smooth vaping experience from broad-spectrum oil in Select Elite Cartridges.

Select delivers premium and consistent quality experience. Curaleaf yearns to introduce more innovative formats from its Select brand in the coming weeks to satisfy the medical patients’ needs.

CEO of Curaleaf, Joe Bayern said Select is part of its family since early last year. The product is well-accepted by the communities in every market it launched. He is pleased to unveil the Select brand to the medical community of Utah. It also takes pride in educating the patients apart from serving high-quality products.

Cannabis is considered essential during the coronavirus pandemic in most of the states. The company is committed to serving the patients with high-quality products while adhering to the highest standards of safety.

Curaleaf operates 101 dispensaries in 23 states. It maintains more than 30 processing sites and 22 cultivation sites.

Continue Reading

Trending Stories